全球冷冻足部治疗市场规模（按产品类型、应用、地区、范围和预测）

冻腿治疗的市场规模及预测

近年来，冻结步态治疗市场规模一直以显着的速度快速增长，预计在市场估计和预测期（2021-2028 年）内将显着增长。

帕金森病患病率的不断上升推动了步态冻结治疗市场的成长。市场进行了全面评估市场。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

全球冷冻足治疗市场的定义

步态冻结（FOG）通常被认为是帕金森氏症的多巴胺抵抗运动症状之一。帕金森氏症是第二常见的神经退化性疾病，影响约 1% 的 60 岁或以上成年人。在85岁以上的人群中，发病率上升至3%至5%。心跳过慢、静止性震颤、僵硬和姿势反射消失是最常见的症状。随着病情的进展，大多数 PD 患者失去姿势反射，导致步态和平衡问题。

弯腰驼背、步态冻结 (FOG)、蹲伏和跌倒都是 PD 中常见的步态障碍。 FOG 被定义为无法解释地无法启动有效步伐的情况，最常见的是在面临障碍物、门口、压力或干扰时启动和转身时出现。最近的研究表明，左旋多巴 (L-dopa) 或恩他卡朋治疗可以改善非相关性 FOG。左旋多巴已被证明可以减少 FOG 发作的持续时间和频率。与 ON 相关的 FOG 很少见且难以诊断。与许多其他疾病一样，FOG 只有在晚期才会对治疗产生抗药性。

迄今为止，左旋多巴是帕金森氏症的黄金标准治疗。左旋多巴显着改善运动症状。与安慰剂或低剂量左旋多巴相比，高剂量左旋多巴可以延缓和减少 FOG 的发作。左旋多巴显着减少了运动不能和眼球震颤发作的次数。左旋多巴还可以减少与 "关" 相关的雾化昏迷的频率和持续时间。深部脑部刺激 (DBS) 已被证明可以改善 FOG 并减少 FOG 的跌倒。

冷冻足部治疗的全球市场概况

帕金森氏症患者病率的不断上升正在推动步态冻结治疗市场的成长。步态冻结是帕金森氏症和其他帕金森氏症的常见症状。步态冻结常常导致跌倒、随后的受伤以及丧失独立性，给患者及其家人带来沉重的负担。步态僵硬的治疗涉及全面的病理生理学，包括其阵发性和多变性、运动（步行机制受损）和非运动（认知障碍、焦虑）障碍的相互作用以及多种神经元连接障碍。各种原因，治疗起来很困难因素，包括复杂（并且可能是异质的）的潜在神经基质。由于该病症与帕金森氏症有关，预计市场将出现健康成长。

全球老年人口的成长是市场发展的最大动力。根据一项研究显示，每年约有6万名北美人被诊断出患有帕金森氏症，因此北美市场潜力巨大。此外，研究发现，男性比女性更容易罹患此类疾病。老年人不仅更容易生病，更容易患上各种慢性和潜在致命的疾病，更容易患上导致终身疼痛的疾病，例如脊椎痛和关节痛。然而，部分患者服用步态冻结相关药物后可能会出现副作用，这可能会抑制步态冻结治疗市场的成长。

目录

第 1 章全球冻伤腿治疗市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 第一次面试
• 资料来源列表

第 4 章 冷冻足治疗的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章 全球冻伤腿治疗市场（依产品类型）

• 概述
• 卡比多巴/左旋多巴
• 深部脑部刺激
• 穿戴式装置和行动辅助设备

• 概述
• 医院
• 诊所
• 其他

第7章 全球冷冻腿治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 8 章 全球冻伤腿治疗市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第9章 公司简介

• Acorda Therapeutics
• Teva Pharmaceuticals
• GYENNO
• MedEXO Robotics
• APDM, INC

第 10 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 11 章附录

• 相关研究

Freezing Of Gait Treatment Market Size And Forecast

Freezing Of Gait Treatment Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. The growing geriatric population worldwide is the biggest driver of the Freezing Of Gait Treatment Market. The Global Freezing Of Gait Treatment Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Freezing Of Gait Treatment Market Definition

Freezing of gait (FOG) is frequently regarded as one of the dopamine-resistant motor symptoms of Parkinsonism. Parkinson's disease is the second most prevalent neurodegenerative disorder, impacting about 1% of adults over 60 years of age. In persons above the age of 85, the incidence rises from 3% to 5%. Bradykinesia, resting tremor, rigidity, and lack of postural reflexes are the most common symptoms. As the disease progresses, most people with PD lose their postural reflexes, leading to walking difficulties and balance problems.

Stooped posture, freezing of gait (FOG) festination, shuffling steps, and falling are all common PD gait disorders. FOG, defined as an onset of inability to start effective steps without a known cause, is most particularly experienced during step initiation and turning, especially facing obstacles, doorways, stress, and distraction. Treatment with levodopa (L-dopa) or entacapone has been shown to improve Off-related FOG in recent studies. L-dopa has been shown to reduce the duration and frequency of FOG episodes. On-related FOGs are uncommon and difficult to diagnose. FOGs, like many other symptoms, are only resistant to treatment at the most advanced stages of the disease.

To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can considerably improve the symptoms of movement. High-dose levodopa can delay and reduce the occurrence of FOG when compared to placebo or low-dose levodopa. Levodopa can significantly decrease the number of episodes of akinesia and FOG. Levodopa can also reduce the frequency and duration of 'off'-related FOG. Deep brain stimulation (DBS) has been shown to improve FOG and reduce falls in FOG.

Global Freezing Of Gait Treatment Market Overview

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. Freezing of gait is a common symptom of Parkinson's syndrome and several other forms of parkinsonism. Freezing is a major burden for both patients and families since it often leads to falls, injuries from falls, and a loss of independence. Treatment of gait freezing is difficult due to a variety of factors, including its paroxysmal and changeable nature; comprehensive pathophysiology encompassing an interplay among motor (disturbed stepping mechanisms) and non-motor (cognitive decline, anxiety); and a complex (and likely heterogeneous) fundamental neural substrate, which includes multiple failing neural connections. As the disease is correlated with Parkinson's disease, the market is expected to grow healthy.

The growing geriatric population worldwide is the biggest driver of the market. According to a study, around 60,000 Americans are diagnosed with Parkinson's disease every year, therefore the market in North America has a lot of potential. Furthermore, it has been discovered that men are more vulnerable to developing such diseases than women. The rise in the geriatric population is also benefitting the Freezing Of Gait Treatment Market, since older people are more likely to become ill and suffer a variety of chronic or fatal diseases, as well as disorders that cause them pain throughout their life, such as spinal or joint pain. However, some patients develop side effects after taking medications related to the freezing of gait which might restrain the Freezing Of Gait Treatment Market growth.

Global Freezing Of Gait Treatment Market: Segmentation Analysis

The Global Freezing Of Gait Treatment Market is segmented on the basis of Product Type, Application, And Geography.

Freezing Of Gait Treatment Market, By Product Type

• Carbidopa/Levodopa
• Deep Brain Stimulation
• Wearable and Walking Aid Devices

Based on Product Type, The market is segmented into Carbidopa/Levodopa, Deep Brain Stimulation, and Wearable and Walking Aid Devices. Carbidopa/Levodopa segment is expected to grow at a significant rate during forecasted years. To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can significantly decrease the number of episodes of akinesia and FOG.

Freezing Of Gait Treatment Market, By Application

• Hospitals
• Clinics
• Others

Based on Application, The market is segmented into Hospitals, Clinics, and Others. The Hospitals segment is expected to grow at a significant rate during the forecasted years. This is owing to, symptomatic and neuroprotective therapies being preferred in Hospitals, according to FDA and other research studies.

Freezing Of Gait Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Freezing Of Gait Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Owing to the increased frequency of Parkinson's disease in North America especially the United States generated the highest revenue share in the Freezing Of Gait Treatment Market. Rising awareness of new medications and therapies, FDA approvals for new drugs, and an expansion in PD care services, as well as an improved reimbursement structure, will fuel demand in the near future.

Key Players

• The "Global Freezing Of Gait Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM, INC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In November 2020: MedEXO Robotics is a Hong Kong-based robotics technology company that recently launched the ExoBeam walking device to help people with Parkinson's disease and other movement disorders. For continuous monitoring, the ExoBeam system consists of a small laser projector that can be attached to the wearer's pants, belt, or cane.
• In January 2018: GYENNO, a Chinese firm that develops technologies to help people with Parkinson's disease and other movement disorders, was showing off its Gait Aid Equipment package at the recent CES 2018 conference in Las Vegas.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FREEZING OF GAIT TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL FREEZING OF GAIT TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Carbidopa/Levodopa
• 5.3 Deep Brain Stimulation
• 5.4 Wearable and Walking Aid Devices

6 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Others

7 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL FREEZING OF GAIT TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Acorda Therapeutics
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Teva Pharmaceuticals
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 GYENNO
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 MedEXO Robotics
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 APDM, INC
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research